Back to Stakeholders
Research, Drug Development & ManufacturingAcademic & Non-Profit Research
Research, Drug Development & ManufacturingAcademic & Non-Profit ResearchUniversities and Colleges with Dedicated Psychedelic Research Groups
Research, Drug Development & Manufacturing

Oregon Health & Science University

United States
1 Trial1 Paper

Researchers at the Social Neuroscience and Psychotherapy (SNAP) Lab at OHSU are investigating the therapeutic potential of psychedelics. Assistant Professor of Psychiatry, Dr Chris Stauffer, is the current director of the lab. SNAP Lab aims to maximize the benefits of therapeutic alliance and psychotherapy through the adjunct use of social psychopharmacology, such as oxytocin, MDMA, and psilocybin. Dr Stauffer led a research team from OHSU in a clinical trial exploring the effects of psilocybin in methamphetamine use disorder. With Oregon becoming the first state to legalize psilocybin-assisted therapy, more research is taking place at OHSU.

Academic Research

1 papers

Published Papers

1

Trial Involvement

1

Distinct Focus Topics

0

Latest Publication

Mar 23, 2026

Quick Facts

Type
hospital
HQ
United States
Website
Visit

Sponsored Trials

1
Not yet recruitingI

Psilocybin for Chronic Pelvic Pain (CPP) in Women: A Pilot Feasibility Study

Start Date
Compounds
Psilocybin

Research Papers

1
Open Accessindividual

Inflammatory biomarker outcomes associated with MDMA-assisted therapy: an open-label exploratory study

This open-label exploratory study (n=23) examined inflammatory biomarkers in Veterans with PTSD during MDMA-assisted group therapy and found small changes in interleukin-6, tumour necrosis factor alpha and C-reactive protein. Higher baseline inflammation was linked with worse PTSD symptoms, and changes in interleukin-6 were related to symptom improvement.

Published
Journal
Frontiers in Neuroscience
Authors
Kachmarik, J. E., Loftis, J. M., Stauffer, C. S.